Chemomab Therapeutics News

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 15 15:31 ET

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11

Moomoo NewsNov 15 14:31 ET

Chemomab Therapeutics Analyst Ratings

BenzingaNov 15 10:55 ET

Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsNov 15 09:33 ET

Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsOct 18 09:34 ET

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsAug 22 13:32 ET

Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer

TipRanksAug 22 07:23 ET

Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsJul 27 08:32 ET

Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9

Moomoo NewsJul 26 08:31 ET

Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13

Moomoo NewsJul 25 15:32 ET

Chemomab Therapeutics Analyst Ratings

BenzingaMay 13 12:34 ET

Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)

TipRanksMay 10 08:35 ET

Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)

TipRanksMay 6 07:55 ET

Chemomab Therapeutics Analyst Ratings

BenzingaMay 6 07:52 ET

Chemomab Therapeutics Analyst Ratings

BenzingaMar 8 08:47 ET

Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target

BenzingaDec 19, 2023 09:14 ET

Chemomab Therapeutics Analyst Ratings

BenzingaDec 19, 2023 09:13 ET

Oppenheimer Reaffirms Their Hold Rating on Chemomab Therapeutics (CMMB)

TipRanksNov 10, 2023 10:06 ET

Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7

BenzingaOct 6, 2023 08:56 ET

Chemomab Therapeutics Analyst Ratings

BenzingaOct 6, 2023 08:55 ET